Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases, has announced a webcast scheduled for August 12, 2024, at 4:30 p.m. Eastern Time. The purpose of this webcast is to discuss the company's financial results for the second quarter ended June 30, 2024, and provide a business update.
Investors and interested parties can access the live webcast through the provided link or via the 'Presentations & Events' section of Belite Bio's Investor Relations website. A replay of the webcast will be available for approximately 90 days after the event, allowing those unable to attend the live session to review the information at their convenience.
Belite Bio (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica concentrata nello sviluppo di nuove terapie per malattie retiniche degenerative, ha annunciato un webcast programmato per il 12 agosto 2024, alle 16:30 ora orientale. Lo scopo di questo webcast è discutere i risultati finanziari del secondo trimestre chiuso il 30 giugno 2024 e fornire un aggiornamento aziendale.
Gli investitori e le parti interessate possono accedere al webcast in diretta tramite il link fornito o attraverso la sezione 'Presentazioni e Eventi' del sito web delle Relazioni con gli Investitori di Belite Bio. Una registrazione del webcast sarà disponibile per circa 90 giorni dopo l'evento, consentendo a coloro che non possono partecipare alla sessione dal vivo di rivedere le informazioni a loro convenienza.
Belite Bio (NASDAQ: BLTE), una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias novedosas para enfermedades retinianas degenerativas, ha anunciado un webcast programado para el 12 de agosto de 2024 a las 4:30 p.m. hora del Este. El propósito de este webcast es discutir los resultados financieros del segundo trimestre que finaliza el 30 de junio de 2024 y proporcionar una actualización del negocio.
Los inversores y las partes interesadas pueden acceder al webcast en vivo a través del enlace proporcionado o en la sección 'Presentaciones y Eventos' del sitio web de Relaciones con Inversores de Belite Bio. Una repetición del webcast estará disponible durante aproximadamente 90 días después del evento, permitiendo a aquellos que no puedan asistir a la sesión en vivo revisar la información a su conveniencia.
Belite Bio (NASDAQ: BLTE)는 퇴행성 망막 질환에 대한 새로운 치료제를 개발하는 임상 단계의 생물 제약 회사로, 2024년 8월 12일 동부 표준시로 오후 4시 30분에 예정된 웹캐스트를 발표했습니다. 이 웹캐스트의 목적은 2024년 6월 30일 종료된 2분기 재무 결과에 대해 논의하고 비즈니스 업데이트를 제공하는 것입니다.
투자자와 관심 있는 당사자는 제공된 링크를 통해 라이브 웹캐스트에 접속하거나 Belite Bio의 투자자 관계 웹사이트의 '프레젠테이션 및 이벤트' 섹션을 통해 접근할 수 있습니다. 웹캐스트의 재생은 이벤트 이후 약 90일 동안 제공될 예정이며, 라이브 세션에 참석할 수 없는 분들이 편리하게 정보를 검토할 수 있도록 합니다.
Belite Bio (NASDAQ: BLTE), une entreprise biopharmaceutique en phase clinique axée sur le développement de nouvelles thérapies pour les maladies dégénératives de la rétine, a annoncé un webinaire prévu pour le 12 août 2024 à 16h30, heure de l'Est. L'objectif de ce webinaire est de discuter des résultats financiers du deuxième trimestre clos le 30 juin 2024 et de fournir une mise à jour sur l'entreprise.
Les investisseurs et les parties intéressées peuvent accéder au webinaire en direct via le lien fourni ou par le biais de la section 'Présentations et Événements' du site Web des Relations Investisseurs de Belite Bio. Une rediffusion du webinaire sera disponible pendant environ 90 jours après l'événement, permettant à ceux qui ne peuvent pas assister à la session en direct de consulter les informations à leur convenance.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung neuartiger Therapien für degenerative Netzhauterkrankungen konzentriert, hat ein Webcast für den 12. August 2024 um 16:30 Uhr Eastern Time angekündigt. Ziel dieses Webcasts ist es, über die Finanzergebnisse des zweiten Quartals, das am 30. Juni 2024 endete, zu berichten und ein Unternehmensupdate zu geben.
Investoren und Interessierte können über den bereitgestellten Link oder über den Bereich 'Präsentationen & Veranstaltungen' auf der Website für Investor Relations von Belite Bio auf das Live-Webcast zugreifen. Eine Wiederholung des Webcasts wird etwa 90 Tage nach der Veranstaltung verfügbar sein, sodass Personen, die nicht an der Live-Sitzung teilnehmen können, die Informationen nach Belieben überprüfen können.
- None.
- None.
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the second quarter ended June 30, 2024.
Webcast Information
Date: Monday, August 12, 2024
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://wsw.com/webcast/cc/blte4/1422018
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When will Belite Bio (BLTE) report its Q2 2024 financial results?
How can investors access Belite Bio's (BLTE) Q2 2024 earnings webcast?
Will there be a replay available for Belite Bio's (BLTE) Q2 2024 earnings webcast?
What is the main focus of Belite Bio (BLTE)?
